Optimization of DE-CTPA Images and Diagnostic Pathway: Using Low Concentration Iodine Contrast Material
Key facts
- Who runs it
- Wuxi People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 2,216 people enrolled
- Started
- 28 Sept 2023
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DE-CTPA with 30 mL iomeprol 300 mg I/mL
- DE-CTPA with 50 mL iomeprol 300 mg I/mL
- DE-CTPA with 50 mL Ioversol 350 mg I/mL
- Record updated
- 29 October 2026
Who can take part
- Age
- 18 years to 97 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age ≥18 years old
- Clinical suspicion of pulmonary embolism suggests CTPA examination (Wells score>4 or age-adjusted D-dimer elevation)
- Patient's general physical condition tolerates CTPA examination
Who cannot take part
- Allergy to iodine contrast agents
- Heart failure patients, NYHA heart function level III or IV
- Hyperthyroidism
- Pregnancy
- Weight greater than 80kg
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators aimed to compare the image quality and diagnostic performance of DECTPA using lower concentration iodine contrast materials and using normal concentration iodine contrast materials in the evaluation of suspected pulmonary embolism.
The 3 groups in the trial
- Protocol A: 30 mL iomeprol 300 mg I/mLTreatment being tested
Participants received 30 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Treatment: DE-CTPA with 30 mL iomeprol 300 mg I/mL
- Protocol B: 50 mL iomeprol 300 mg I/mLTreatment being tested
Participants received 50 mL of iomeprol (300 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Treatment: DE-CTPA with 50 mL iomeprol 300 mg I/mL
- Protocol C: 50 mL Ioversol 350 mg I/mLExisting treatment, for comparison
Participants received 50 mL of Ioversol (350 mg I/mL) at an injection rate of 4.0 mL/s, followed by a 30-mL saline chaser.
Treatment: DE-CTPA with 50 mL Ioversol 350 mg I/mL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dual Energy CT Angiography in Suspected Pulmonary Embolism: Influence of Concentration of Contrast Materials on Image Quality and Diagnostic Performance
- Record updated
- 29 October 2026